122 related articles for article (PubMed ID: 38701770)
1. Sensor macrophages derived from human induced pluripotent stem cells to assess pyrogenic contaminations in parenteral drugs.
Abdin SM; Mansel F; Hashtchin AR; Ackermann M; Hansen G; Becker B; Kick B; Pham N; Dietz H; Schaniel C; Martin U; Spreitzer I; Lachmann N
Biofabrication; 2024 May; 16(3):. PubMed ID: 38701770
[TBL] [Abstract][Full Text] [Related]
2. Monocyte activation test (MAT) reliably detects pyrogens in parenteral formulations of human serum albumin.
Perdomo-Morales R; Pardo-Ruiz Z; Spreitzer I; Lagarto A; Montag T
ALTEX; 2011; 28(3):227-35. PubMed ID: 21993958
[TBL] [Abstract][Full Text] [Related]
3. Assay of pyrogens by interleukin-6 release from monocytic cell lines.
Taktak YS; Selkirk S; Bristow AF; Carpenter A; Ball C; Rafferty B; Poole S
J Pharm Pharmacol; 1991 Aug; 43(8):578-82. PubMed ID: 1681074
[TBL] [Abstract][Full Text] [Related]
4. An improved monocyte activation test using cryopreserved pooled human mononuclear cells.
Solati S; Aarden L; Zeerleder S; Wouters D
Innate Immun; 2015 Oct; 21(7):677-84. PubMed ID: 25907070
[TBL] [Abstract][Full Text] [Related]
5. The monocyte activation test detects potentiated cytokine release resulting from the synergistic effect of endotoxin and non-endotoxin pyrogens.
Solati S; Zhang T; Timman S
Innate Immun; 2022 Apr; 28(3-4):130-137. PubMed ID: 35491666
[TBL] [Abstract][Full Text] [Related]
6. Validation of the monocyte activation test with three therapeutic monoclonal antibodies.
Daniels R; Van der Elst W; Dieltjens N; Appels T; So CK; Nys T; Voeten L; Breugelmans P; Molenaar-de Backer MWA; Gitz E; Poole S; Patel M
ALTEX; 2022; 39(4):621–635. PubMed ID: 35502618
[TBL] [Abstract][Full Text] [Related]
7. Assessment of pyrogenic response of lipoteichoic acid by the monocyte activation test and the rabbit pyrogen test.
Gimenes I; Caldeira C; Presgrave OA; de Moura WC; Villas Boas MH
Regul Toxicol Pharmacol; 2015 Oct; 73(1):356-60. PubMed ID: 26232706
[TBL] [Abstract][Full Text] [Related]
8. Speeding up pyrogenicity testing: Identification of suitable cell components and readout parameters for an accelerated monocyte activation test (MAT).
Stoppelkamp S; Würschum N; Stang K; Löder J; Avci-Adali M; Toliashvili L; Schlensak C; Wendel HP; Fennrich S
Drug Test Anal; 2017 Feb; 9(2):260-273. PubMed ID: 27121912
[TBL] [Abstract][Full Text] [Related]
9. Application of a TLR overexpression cell model in pyrogen detection.
Han Q; Hu R; Li H; Lei Z; Zhang X; Yu X; Zhang Q; Mao Y; Wang X; Irwin DM; Niu G; Tan H
Biotechnol Bioeng; 2019 Jun; 116(6):1269-1279. PubMed ID: 30684361
[TBL] [Abstract][Full Text] [Related]
10. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype.
Quero L; Hanser E; Manigold T; Tiaden AN; Kyburz D
Arthritis Res Ther; 2017 Nov; 19(1):245. PubMed ID: 29096690
[TBL] [Abstract][Full Text] [Related]
11. Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations.
Valentini S; Santoro G; Baffetta F; Franceschi S; Paludi M; Brandini E; Gherardini L; Serruto D; Capecchi B
Vaccine; 2019 Jun; 37(29):3754-3760. PubMed ID: 30448065
[TBL] [Abstract][Full Text] [Related]
12. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.
Dolganiuc A; Norkina O; Kodys K; Catalano D; Bakis G; Marshall C; Mandrekar P; Szabo G
Gastroenterology; 2007 Nov; 133(5):1627-36. PubMed ID: 17916356
[TBL] [Abstract][Full Text] [Related]
13. Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes.
Poole S; Thorpe R; Meager A; Gearing AJ
Dev Biol Stand; 1988; 69():121-3. PubMed ID: 3265674
[TBL] [Abstract][Full Text] [Related]
14. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions.
van Wilgenburg B; Browne C; Vowles J; Cowley SA
PLoS One; 2013; 8(8):e71098. PubMed ID: 23951090
[TBL] [Abstract][Full Text] [Related]
15. Material-mediated pyrogens in medical devices: Applicability of the in vitro Monocyte Activation Test.
Borton LK; Coleman KP
ALTEX; 2018; 35(4):453-463. PubMed ID: 29901209
[TBL] [Abstract][Full Text] [Related]
16. Cryopreservation of human monocytes for pharmacopeial monocyte activation test.
Koryakina A; Frey E; Bruegger P
J Immunol Methods; 2014 Mar; 405():181-91. PubMed ID: 24456627
[TBL] [Abstract][Full Text] [Related]
17. The use of human monocytoid lines as indicators of endotoxin.
Eperon S; Jungi TW
J Immunol Methods; 1996 Aug; 194(2):121-9. PubMed ID: 8765165
[TBL] [Abstract][Full Text] [Related]
18. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis.
Gaines Das RE; Brügger P; Patel M; Mistry Y; Poole S
J Immunol Methods; 2004 May; 288(1-2):165-77. PubMed ID: 15183094
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonication of pyrogenic microorganisms improves the detection of pyrogens in the Mono Mac 6 assay.
Moesby L; Hansen EW; Christensen JD
Eur J Pharm Sci; 2000 Jul; 11(1):51-7. PubMed ID: 10913753
[TBL] [Abstract][Full Text] [Related]
20. Performance of monocyte activation test supplemented with human serum compared to fetal bovine serum.
Molenaar-de Backer MWA; Gitz E; Dieker M; Doodeman P; Ten Brinke A
ALTEX; 2021; 38(2):307-315. PubMed ID: 33118606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
